Prometheus Laboratories has received a new US patent related to the protection of a flagellin peptide useful in the detection of antibodies to the flagellin CBir1, or anti-CBir1, for determining the presence of inflammatory bowel disease.
Prometheus said that this proprietary technology is used in the company's Prometheus IBD serology 7 test and its recently launched Prometheus IBS diagnostic test. Prometheus has exclusive rights to this technology under an agreement with Corixa.
The patent provides a means of detecting the presence and levels of CBir1 antibodies in a patient sample.
Prometheus IBS diagnostic is said to be the first blood-based biomarker test to help physicians diagnose irritable bowel syndrome (IBS). Prometheus said that its IBD serology 7 is the most comprehensive inflammatory bowel disease (IBD) diagnostic testing service available to help physicians detect IBD and differentiate between Crohn's disease and ulcerative colitis.